Cardiol Therapeutics Inc Class A (CRDL.TO) faced a setback in the market today, with shares dropping 0.65%.
In the latest trading session, Cardiol Therapeutics Inc Class A saw its stock price decline to CA$1.53, marking a 0.65% drop. This downturn comes amidst a lack of significant news to explain the movement, leaving investors questioning the future direction of the company.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While the decline is modest, it highlights a potential lack of investor confidence and the need for Cardiol Therapeutics to provide clearer communication on its operational progress and financial health.
Cardiol Therapeutics Inc Class A shares down 0.65% today
The decline in stock price reflects a broader sentiment of caution among investors, especially in light of the company's recent performance and market conditions.
Bull case
Cardiol Therapeutics has made progress in its clinical trials, especially with the Phase III MAVERIC trial and promising Phase II ARCHER data. If these trials succeed, they could pave the way for future growth.
Bear case
The lack of recent positive news and ongoing volatility in the biotech sector may put off investors, potentially leading to further declines if confidence doesn’t improve.
Market Performance Overview
Cardiol Therapeutics Inc Class A's stock performance today reflects a 0.65% decline, closing at CA$1.53. This drop is notable given the lack of recent news that could have influenced investor sentiment. The market cap currently stands at approximately CA$171.76 million, indicating a cautious outlook from investors.
Investor Sentiment and Future Outlook
The recent decline in Cardiol Therapeutics' stock price raises questions about investor confidence. Despite positive developments in clinical trials, the absence of impactful news may lead to increased volatility. Investors are advised to monitor the company's upcoming announcements closely, particularly regarding trial results and operational updates. For more insights, check out the latest updates on Cardiol Therapeutics.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
